Treatment Strategy of a Recurrent Squamous Cell Pancreatic Carcinoma with Peritoneal Carcinomatosis | Chapter 7 | New Visions in Medicine and Medical Science Vol. 7

Background: Pancreatic squamous cell carcinoma is an uncommon condition, and little is known about its pathogenesis. The only possible curable procedure is surgical resection. Palliative care is typically administered for recurrent local-regionally located pancreatic carcinomas, as they are typically incurable.
 
Aim: The purpose of the study is to present the treatment strategy of a recurrent squamous cell pancreatic carcinoma with peritoneal carcinomatosis.
 
Case Report: A 49-year-old man with local-regional recurrent squamous cell pancreatic carcinoma underwent complete (CC-0) cytoreductive surgery (CRS) and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC). In a 6-month time he underwent secondary CRS+HIPEC for regional recurrence.
 
Despite treatment with adjuvant systemic chemotherapy the patient died 12 months after the initial CRS with osseous metastases. The biologic behavior and the clinical presentation do not differ from ductal adenocarcinoma of the pancreas, although upper gastrointestinal tract bleeding secondary to gastric invasion appears to be more frequent in squamous cell pancreatic carcinomas.
 
Conclusions: A reliable prognosis for recurrent squamous cell pancreatic carcinoma is difficult despite complete cytoreduction in combination with HIPEC and systemic chemotherapy. The patient presented recurrence despite aggressive treatment shortly after surgery. Although complete cytoreduction was possible very shortly the patient presented distant metastatic disease and died.

Author(s) Details:

A. Tentes,
Euromedica Kyanous Stavros, Thessaloniki, Greece.

A. Fotiadou,
Laboratory of Diagnostic Histopathology, Greece.

D. Kyziridis,
Euromedica Kyanous Stavros, Thessaloniki, Greece.

Ch. Hristakis,
Euromedica Kyanous Stavros, Thessaloniki, Greece.

A. Kalakonas,
Euromedica Kyanous Stavros, Thessaloniki, Greece.

A. Iliadis,
Laboratory of Diagnostic Histopathology, Greece.

Please see the link here: https://stm.bookpi.org/NVMMS-V7/article/view/14224

2017 Update on Ovarian Cancer Peritoneal Carcinomatosis Multimodal-Treatment Considerations: A Brief Review | Chapter 13 | Highlights on Medicine and Medical Research Vol. 7

 Peritoneal carcinomatosis caused by ovarian cancer necessitates a multimodal treatment strategy. The management of recurrent malignant ascites and understanding its pathophysiology, the role of peritoneal washing cytology in detecting peritoneal metastases, capsular invasion and ovarian cancer histologic type, and interpretation of pretreatment Ca-125 levels at different time points of ovarian cancer therapeutic management are all discussed in this update. This update also covers current thoughts on the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer peritoneal carcinomatosis, as well as current phase III randomised controlled trial methods. Patients with advanced ovarian cancer who have a full resection do not need to have a systematic lymphadenectomy, according to the findings of the study.

Author(s) Details

Evgenia Halkia
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece and American Society of Peritoneal Surface Malignancies (ASPSM), Clarkesville, MD, USA.

George Chrelias
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Charalambos Chrelias
3rd Gynecologic Clinic, University Teaching Hospital “Attikon”, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Jesus Esquivel
American Society of Peritoneal Surface Malignancies (ASPSM), Clarkesville, MD, USA and General and Oncology Surgery Clinic, Frederick Memorial Hospital, Frederick, MD, USA.

View Book :- https://stm.bookpi.org/HMMR-V7/article/view/1070